CA-POSIFLEX
5.1.2022 18:02:06 CET | Business Wire | Press release
Posiflex is pleased to join National Retail Federation’s Big Show for 2022 and will be showcasing its latest point-of-sale solutions in booth #5919. After a two-year-long hiatus from a live NRF show, anticipation is at an all-time high, and Posiflex is excited to exhibit its full line of point-of-sale (POS) terminals, kiosks, tablets and more—along with a few surprises—optimized for retailers in search of powerful and flexible post-pandemic solutions for their operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220105005004/en/
In addition, Posiflex will showcase a new line of POS terminals for today’s retail demands, including the versatile XT7315 , and exciting, fresh models from the new RT6000 Series: the RT6015 and RT6016 .
The XT7315 comes with a wide selection of processors that can suit virtually any point-of-sale requirement. Running on Windows 10 IoT Enterprise OS platform, the XT7315 is housed in a stylish, durable exterior and has a well-designed base that allows for optimal cable management. With its choice of processors, plus a multi-position folding base and a fanless design, the XT7315 continues the excellence of quality and performance that the line of Posiflex XT Series is well-known for.
The new RT6000 Series includes two models: the RT6015 and RT6016, both providing a selection of Intel processors geared for maximum performance and uptime. The main difference between the two models is the display size, with the RT6015 having a 15”/4:3 standard-ratio touch screen display and the RT6016 having a 15.6”/16:9 widescreen-ratio touch screen display. Running on Windows 10 IoT Enterprise and sporting the same exceptional characteristics from the RT Series family, including sleek aesthetics, durability, performance, and reliability, the Posiflex RT6000 Series is an ideal fit for Retail, Hospitality or Specialty-Service establishments.
“With rigorous HALT/HASS testing and total in-house manufacturing that all our products experience, our new XT7315 and RT6000 terminals extend the Posiflex legacy of providing top-notch point-of-sale hardware for today’s challenging atmosphere and customers’ demands,” says Doyle Ledford, VP of Sales & Marketing for Posiflex. “We look forward to introducing these exceptional products along with the rest of our latest solutions at NRF 2022.”
About Posiflex
Since 1984, Posiflex has designed and manufactured award-winning POS terminals and peripherals. Posiflex has since grown exponentially to provide not only full-service POS stations, but also versatile self-service kiosks, state-of-the-art mobile tablets, and scalable embedded PC solutions. Renowned worldwide in the retail and hospitality industries, Posiflex is a proven leader in POS hardware for Windows and Android OS. More than 30 patents and numerous awards have been won for product innovation, design, and reliability. https://www.posiflexusa.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
